Health Chat Transcripts
Mission Statement
As part of the Cleveland Clinic’s Neurological Institute, the Mellen Center for Multiple Sclerosis offers state-of-the-art resources to provide the most advanced specialized care, supported by an extensive program of research and education. The Mellen Center is the largest and most comprehensive program for MS care and research worldwide, managing more than 20,000 patient visits every year. Basic and clinical research conducted at the Cleveland Clinic sheds new light on MS every year.
The center’s mission statement is guided by these fundamental principles:
- To provide you and your family with compassionate, comprehensive, innovative and technologically advanced care of the highest quality.
- To conduct clinical and basic research of national and international distinction.
- To educate clinicians, academicians, investigators and allied health care providers about MS and to promote the education of our patients, their families and the general public about the disease.
Please Note: The Mellen Center does not provide Remote Medical Second Opinions.
News from the Mellen Center
MS in Focus - Issue 16
View the newest issue of MS in Focus
What’s New in MS Research and Treatment
Dr. Fox was recently asked to talk about CCSVI and research into this topic on a National MS society webcast. Other MS researchers also comment on new directions in MS in this webcast. Dr. Fox's component is later in the program at 54 minutes. View the CCSVI Webcast with Dr. Fox
Mellen Center receives large grant from the National MS society to perform a study of CCSVI in MS patients
The Mellen Center Staff, under the direction of Dr. Robert J. Fox, our medical director, recently received an important grant from the National MS society to study ‘chronic cerebrospinal venous insufficiency’ (CCSVI), a new theory of what causes MS. The project will evaluate individuals with MS and compare their ultrasound and MR venography results with those of healthy controls and individuals with other neurological and autoimmune disorders. We are pleased to have this opportunity to scientifically and objectively evaluate this possible link between multiple sclerosis and the blood flow out of the brain and spinal cord....
read more
Investigational Oral Compound to Treat MS Effective, According to Phase III Trial
Two oral medications (pills) to treat multiple sclerosis have received recent attention, fingolimod (also known as FTY720) and cladribine. These are not pill forms of medications already-approved for MS (Avonex, Betaseron, Copaxone, Extavia, Novantrone, Rebif, and Tysabri) but are new medications...
read more
Chronic cerebrospinal venous insufficiency in relation to MS
Recent publications from a center in Italy have raised the idea that patients with MS may have an increased risk of narrowing of the veins draining the brain and spinal cord...
read more
Cleveland Clinic Receives $2.75 Million Grant To Study Stem Cell Treatment For MS
Jeffrey Cohen, MD, of Cleveland Clinic’s Mellen Center, will conduct a Phase I study to determine the feasibility and safety of using mesenchymal stem cells to treat MS...read more
